Antenatal steroids result in fetal lung maturation, but may retard brain development. Auditory brainstem-evoked response (ABR) is a noninvasive assessment of brainstem maturation. The objective of this study was to determine if antenatal steroids affect brainstem maturation in infants r32 weeks gestational age (GA).
INTRODUCTION
A National Institute of Health (NIH) consensus statement in 1994 endorsed use of antenatal steroids for fetal lung maturation in premature infants, but indicated need for future work on its effect on other organ maturation. 1 At the time of the NIH consensus statement, it was known that maternal glucocorticoids delay myelination and reduce growth of fetal brains in animal studies. 1 However, these animal studies were conducted using doses approximately 10 times the doses used in human clinical trials. 1, 2 Recently, studies at the molecular level using smaller doses of steroids, comparable to those in human clinical trials, have demonstrated alteration of nuclear transcription factors that regulate brain cell differentiation, alteration of neuronal cytoskeleton, and morphological alteration of synapses. [3] [4] [5] Functionally, antenatal steroids have also been shown to suppress central nervous system-dependent biophysical activities including the brainstem-dependent vibro-acoustic startle reflex in human fetuses. 6 Based on these findings, it is plausible that there could be an acute adverse effect of antenatal steroids on brainstem maturation.
Auditory brainstem-evoked response (ABR) has been clinically used as a noninvasive neurophysiological assessment of brainstem maturation and function during early development. [7] [8] [9] This test measures conduction time both peripherally and centrally. The ABR waveform in neonates is often comprised of three waves (I, III and V). Electrophysiologic data have shown that wave I is generated peripherally in the auditory nerve. 10 Wave III reflects the firing of axons exiting the cochlear nuclear complex in the brainstem, while wave V primarily reflects an action potential generated by axons from the lateral lemniscus at a more rostral brainstem location. 10 Interpeak latencies (I to III, III to V, I to V) reflect nerve conduction velocity. 11 Axonal growth, synaptic function, and degree of myelination influence the ABR waveform. 12 In the premature infant, ABRs mature with increasing gestational age (GA). 13 Maturational changes include the appearance of specific waves and a decrease in absolute wave latencies and interpeak latencies. To determine if antenatal steroids have an effect on the ABR maturational pattern, we tested premature infants at r32 weeks GA whose antenatal steroid status was determined by their attending obstetrician.
SUBJECTS AND METHODS

Patient population
A total of 234 infants at r32 weeks GA at birth were admitted to the Neonatal Intensive Care Unit (NICU) of Strong Children's Hospital from July 1996 to December 1997. All infants r32 weeks GA at birth were eligible for this study unless they had craniofacial anomalies (n ¼ 3), chromosomal disorders (n ¼ 1), TORCH infection (n ¼ 2) or were too clinically unstable for ABR testing within the first 24 hours after birth (n ¼ 32). A total of 10 infants were not studied because of the unavailability of audiologists to perform ABR. GA was assessed by obstetrical dating criteria or, when obstetrical data were inadequate, by Ballard exam. For analysis, data were grouped by GA at the time of birth in 2-week intervals: 24 ); and 30 to 31 (30 0/7 to 32 0/7 ) gestation. At the time of the study, the recommended antenatal glucocorticoid regimen consisted of the administration to the mothers of two 12-mg doses of betamethasone given intramuscularly 24 hours apart. Infants whose mothers had been given any betamethasone at any time before birth to accelerate fetal lung maturation constituted the antenatal steroid group. The remainder of infants constituted the nonantenatal steroid (control) group. Among the antenatal steroid group, patients were subgrouped into two: (1) who received at least one complete antenatal course and (2) who received partial antenatal steroid therapy. Data were also collected for mode of delivery, chorioamnionitis, in utero exposure to cocaine and other illicit drugs, use of magnesium sulfate (MS), 5 minute Apgar <5 and mechanical ventilation at the time of ABR testing.
Auditory brainstem evoked response
ABRs were recorded with a Biological Navigator-Evoked Response System with the subjects lying supine in the isolette and a skin temperture of >35.51C. Testing was performed by audiologists skilled in the administration of ABR tests to NICU infants. Electrode sites were mastoid (reference), midline on high forehead or crown of the head (active) and shoulder (ground). Electrode gel was applied to silver/silver chloride electrodes. Bilateral monaural ABR tests were performed within first 24 hours of postnatal life using 80 dB nHL broadband click stimuli with supra-aural earphones. The clicks were presented at a repetition rate of 39.9/second, and three runs of 2000 repetitions were recorded for each ear. The two most replicable runs for each ear were averaged and used for analysis. The ABRs were analyzed by the audiologists without knowledge of GA or antenatal steroid status.
Since ABR waves I, III and V cannot be detected in all premature infants at r32 weeks, ABR waveforms were categorized into Response Types based on response replicability and peak identification: Type 1, a waveform with normal morphology and replicable waves III and V; Type 2, a replicable response with either a wave III or V; Type 3, a replicable response with neither a wave III or V; Type 4, a waveform with no replicable response ( Figure 1 ). If the waveform was Type 1 or Type 2, latencies for waves I, III, and V, and interpeak latencies 1 to III, III to V and I to V were measured. The better ear's response was used for final analysis. The study was approved by Human Subject Review Board.
Sample size calculations and statistical analysis An approximate sample size was determined for the number of neonates to be studied based on earlier findings of ABR maturation Multiple regression analysis was done to assess the independent relations of multiple variables with measured ABR parameters. All tests were two sided and a P<0.05 was considered statistically significant.
RESULTS
Demographics
A total of 186 infants were studied. Of these, 130 infants received antenatal betamethasone, while 56 infants did not. Of 130 infants who received antenatal betamethasone, 98 infants received at least one complete course of steroid and 25 infants received partial antenatal steroid therapy. For seven infants who were transferred from other hospitals, it was unclear whether infants received partial or complete antenatal steroid therapy. The mean time interval between partial antenatal steroid therapy and birth of 25 infants was 14 hours. The demographics of the study patients are shown in Table 1 . There was no significant difference in maternal chorioamnionities, in utero exposure to illicit drugs, rate of csection delivery, 5 minute Apgar <5 minutes or use of mechanical ventilation at the time of testing between infants in the two groups. There was a significant difference in birth weight, race, and maternal treatment with MS between groups.
Wave latencies
The mean absolute and interpeak latencies as a function of antenatal steroid therapy for the study population are shown in Table 2 . There was no significant difference in mean latencies for wave V between 28-and 29-week GA infants who received antenatal steroid therapy and those who did not (p ¼ 0.52). Owing to the inability to reliably detect waves I and III, there were insufficient data to calculate and compare wave I and III latencies and the interpeak latencies. In 30-to 31-week GA infants, there were no differences in latencies for wave I (p ¼ 0. Owing to the inability to detect waves reliably in 24-to 25-and 26-to 27-week GA infants, mean latencies could be calculated from very few observations and are not shown. The differences in absolute latencies and interpeak latencies between the two groups remained insignificant when GA, birthweight, race, maternal treatment with MS, chorioamnionities, in utero exposure to illicit drugs and 5 minute Apgar <5 minutes were controlled using multiple regression model.
On subanalysis of the data for 30-to 31-week GA infants, we found no differences in latencies for wave I (p ¼ 0. 
Response Types
The frequency distribution of Response Types among nonantenatal steroid and antenatal steroid groups is shown in Table 3 . Although there was a trend for increased frequency of more mature Response Types (Types 1 and 2) in the antenatal steroid group, there was no significant difference in frequency distribution of Response Types among infants of any GA as a function of antenatal steroid exposure (p ¼ 0.70). The difference in the frequency distribution of Response Types between the two groups remained insignificant (p ¼ 0.42) after controlling for GA, birth weight, race, maternal treatment with MS, chorioamnionities, in utero exposure to illicit drugs and 5 minute Apgar <5 minutes using multiple regression model. On subanalysis of the data, there was no significant difference in frequency distribution of Response Types among infants of any GA between infants who did not receive antenatal steroid therapy and who received at least one complete course of antenatal steroid therapy (p ¼ 0.50). Also, the difference in frequency distribution of Response Types among infants of any GA between infants who received partial antenatal steroid therapy and infants who received at least one complete course of antenatal steroid therapy was not significant (p ¼ 0.37).
DISCUSSION
Recent findings in animal studies of alteration of nuclear transcription factors that regulate brain cell differentiation, alteration of neuronal cytoskeleton, and morphological alteration of synapses with clinically relevant doses of antenatal steroids raise concerns about their acute harmful effect on developing human brain. [3] [4] [5] Our findings suggest that antenatal treatment with betamethasone, as currently recommended, has no acute harmful or beneficial effect on brainstem maturation as evaluated by ABR.
A meta-analysis of the effects of postnatal steroid therapy suggested that steroids at any age and at any dose may be unsafe for the developing brain. 14, 15 In addition, recently published retrospective studies have documented dose-dependent increases in adverse outcomes following multiple courses of antenatal corticosteroids. 16, 17 This is consistent with the findings in animal studies that cortisol impairs myelination and cellular development in the developing central nervous system. 2, 18, 19 Since the differences between humans and laboratory animals are in the timing of the brain growth spurt and the complexity of the mature brain and not in the overall sequence of brain growth, the results of the animal studies may provide a partial explanation for the clinical findings. 20 In humans, most of the neuronal division is completed by 24 weeks of gestation. After 24 weeks of gestation, cell division in the brain involves mainly the oligodendroglial cells, which will lay down myelin. 20 The relatively long half-life of steroids in premature infants may also contribute to the likelihood of effects on the developing brain. 21 The ABR has been used as a noninvasive objective measure to evaluate brain maturation in infants with transient thyroxinemia, as a function of enteral feeding and to evaluate the need for taurine supplementation for brain maturation in premature infants. [7] [8] [9] Considerable synaptogenesis, dendritic growth and myelination occur in the auditory pathway in the prenatal and postnatal period. Since the ABR waveform is influenced by these developmental changes in auditory pathway, the ABR can be used to evaluate the effect of exogenous influences such as steroid therapy on brainstem maturation. Since the ability to detect unambiguously identifiable waves in infants at <32 weeks GA is limited, assigning a category to the ABR may increase the usefulness of ABR for evaluating and monitoring neurophysiological function in premature infants. 13 Earlier studies have shown that there are progressive maturational changes in ABR parameters including Response Types, absolute latencies and interpeak latencies with increasing GA. 12, 13 On evaluating the effect of antenatal steroid therapy on ABR maturational changes, we found a trend for increased prevalence of more mature Response Types (1 and 2) in the antenatal steroid group for both 28 to 29 and 30 to 31 weeks' GA This lack of effect of antenatal steroid therapy on brainstem maturation as measured by the ABR may reflect a similar lack of effect on maturation of other parts of the brain. The absence of a deleterious effect on brainstem maturation may also be clinically relevant because the degree of brainstem maturation may affect the frequency of other clinical entities such as apnea of prematurity. 22 Our study does not address specifically the effect of multiple vs single course of betamethasone on brainstem maturation. However, despite contamination of the steroid group with the multiple courses, we have not found any acute adverse effect on brainstem maturation. It is therefore unlikely to see an adverse effect with the recent recommendations of NIH consensus statement to use single course of antenatal corticosteroids outside randomized trials. 23 Our study also does not address the effect of dexamethasone or possible difference in neurotoxicity between betamethasone and dexamethasone. Recently, a report associated antenatal dexamethasone with an increased incidence of periventricular leukomalacia compared to antenatal betamethasone. 24 In summary, use of antenatal betamethasone in humans, as recommended by the NIH consensus statement, is likely to have no acute harmful effects on brainstem maturation specifically or on developing human brain in general.
